Latest Articles
February 19, 2025
Three Benefits of Ordering Exome Testing as Trios
Several studies have shown that running an exome “trio” with both biological parents increases the diagnostic yield and decreases the rates of variants of uncertain…
Family History
Genetic Testing
Genetic Testing Accuracy
Whole Exome Sequencing
February 4, 2025
Why Consider an Exome-First Testing Workflow?
Evaluating rare disease and neurodevelopmental disorders focuses on chromosomal microarray (CMA) or exome sequencing. We explore the benefits of these testing methods and why exome-first…
Whole Exome Sequencing
January 15, 2025
From Fear to Empowerment: A Patient’s Perspective on the Ambry CARE Program
The Ambry CARE Program® helps providers identify high-risk patients, offers genetic testing and genetic counseling at scale, and gives patients insights to help them better…
BRCA
BRCA2
Breast Cancer
Cancer Previvor
Colorectal Cancer
Ovarian Cancer
Prevention
Previvor
December 18, 2024
Enhancing Patient Care: A Digital Approach via The Ambry CARE Program® Improves Universal Cancer Risk Stratification in Imaging Centers
A retrospective study across 15 Imaging Centers assesses the transition of a paper screening cancer risk assessment tool to a universally accessible tool on a…
Genetic Testing
Hereditary Cancer
OBGYN
Screening
December 17, 2024
Navigating Hereditary Cancer Testing: Selecting the Right Multigene Panel
For healthcare providers, choosing the right hereditary cancer test and laboratory is crucial to offer the best care for their patients.
Genetic Testing
Hereditary Cancer
Multigene Panel Testing
December 4, 2024
Understanding Gene-Disease Validity in Hereditary Cancer Testing
Gene-Disease Validity (GDV) discussed as an important concept for evaluating hereditary cancer multigene panel tests (MGPTs).
Genetic Testing
Hereditary Cancer
![overlay-bottom[1]](https://ambrygen.com/wp-content/uploads/2026/02/overlay-bottom1.svg)